Anchiano Therapeutics initiated with an Outperform at Oppenheimer. Oppenheimer analyst Leland Gershell initiated Anchiano Therapeutics with an Outperform rating and $16 price target. In a research note to investors, Gershell says Anchiano is committed to expanding treatment options for non-muscle invasive bladder cancer through its development of inodiftagene, a targeted biotherapeutic.
https://thefly.com/landingPageNews.php?id=2877025
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.